Literature DB >> 6106395

Tardive dyskinesia: review and update.

H L Klawans, C G Goetz, S Perlik.   

Abstract

Tardive dyskinesia is an extrapyramidal syndrome associated with the chronic administration of major neuroleptic agents. The pathogenesis of the disorder appears to relate to chronic striatal dopaminergic receptor site blockade; the pathophysiology of tardive dyskinesia appears to relate to the resultant denervation hypersensitivity. Agents that deplete the brain of dopamine are the mainstay of therapy for tardive dyskinesia. Cholinergic agents that potentially modulate the balance between dopamine and acetycholine in the striatum offer possible additional therapeutic options. Clearly, resumption of neuroleptic therapy is treatment with the presumed pathogenic agent and is to be avoided whenever possible.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6106395     DOI: 10.1176/ajp.137.8.900

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  29 in total

1.  The management of neuroleptic-induced CNS effects.

Authors:  B F Hoffman; M V Seeman
Journal:  Can Fam Physician       Date:  1981-10       Impact factor: 3.275

2.  Psychiatry-epitomes of progress: tardive dyskinesia.

Authors:  T V Putten
Journal:  West J Med       Date:  1981-02

3.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

4.  Abnormal involuntary movements: side-effect of neuroleptic drugs.

Authors:  L K Oyewumi
Journal:  Can Fam Physician       Date:  1982-01       Impact factor: 3.275

5.  Characterization of [3H]clozapine binding sites in rat brain.

Authors:  I Kusumi; S Matsubara; Y Takahashi; T Ishikane; T Koyama
Journal:  J Neural Transm Gen Sect       Date:  1995

6.  A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons.

Authors:  M P Smidt; H S van Schaick; C Lanctôt; J J Tremblay; J J Cox; A A van der Kleij; G Wolterink; J Drouin; J P Burbach
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

7.  Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function.

Authors:  J G Csernansky; S Glick; J Mellentin
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

8.  Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.

Authors:  T M Hyde; M F Egan; L L Wing; R J Wyatt; D R Weinberger; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 9.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

10.  Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.

Authors:  Aoi Syu; Hiroki Ishiguro; Toshiya Inada; Yasue Horiuchi; Syunsuke Tanaka; Maya Ishikawa; Makoto Arai; Masanari Itokawa; Kazuhiro Niizato; Shuji Iritani; Norio Ozaki; Makoto Takahashi; Akiyoshi Kakita; Hitoshi Takahashi; Hiroyuki Nawa; Kazuko Keino-Masu; Eri Arikawa-Hirasawa; Tadao Arinami
Journal:  Neuropsychopharmacology       Date:  2010-01-13       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.